Announced details
Prevention of acute ischemic brain injury in hemodialysis patients
Dosing administered to the first patient
Co-developing AV-001.
A Canadian privately held biopharmaceutical company focused on clinical-stage development. Founded in 2014, it is headquartered and operates a research facility in Toronto, Canada, and also has a location in Raleigh, North Carolina, USA. The company is developing next-generation therapeutics that enhance the body's natural defenses against vascular leakage. Its representative is CEO Dr. Brian E. Jahns.
Toronto, Canada (headquarters and research facility); Raleigh, North Carolina, USA
No impact on consolidated results for the fiscal year ending December 2026.
The company does not address Contract Value / Offering price.
Approval by Health Canada and a grant from the Heart and Stroke Foundation
| Item | Details |
|---|---|
| Names of Products / Services Covered | Pegevongitide (Tie2 receptor agonist) AV-001 |
| Counterparty | Vasomune Therapeutics, Inc. |
| Counterparty overview | A Canadian privately held biopharmaceutical company focused on clinical-stage development. Founded in 2014, it is headquartered and operates a research facility in Toronto, Canada, and also has a location in Raleigh, North Carolina, USA. The company is developing next-generation therapeutics that enhance the body's natural defenses against vascular leakage. Its representative is CEO Dr. Brian E. Jahns. |
| Relationship with the Company | Co-developing AV-001. |
| Launch date | 25 March 2026 (dosing of the first patient initiated, actual) |
| Applicable area | Prevention of acute ischemic brain injury in hemodialysis patients |
| Location | Toronto, Canada (headquarters and research facility); Raleigh, North Carolina, USA |
| Usage history | Dosing administered to the first patient |
| Impact on Business Performance | No impact on consolidated results for the fiscal year ending December 2026. |
| Source | Approval by Health Canada and a grant from the Heart and Stroke Foundation |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.A clinical trial will be conducted to evaluate the safety and efficacy of AV-001 in preventing recurrent ischemic brain injury caused by hemodynamic stress during hemodialysis.